STABILITY INDICATIVE AND COST EFFECTIVE ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF FAVIPIRAVIR AND PERAMIVIR IN BULK AND PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC
Objective: The current investigation was pointed at developing and progressively validating novel, simple, responsive and stable RP-HPLC method for the measurement of active pharmaceutical ingredients of Favipiravir and Peramivir and their related substances.
Methods: A simple, selective, validated and well-defined stability that shows gradient RP-HPLC methodology for the quantitative determination of Favipiravir and Peramivir. The chromatographic strategy utilized Inertsil ODS column of dimensions 250x4.6 mm, 5 micron, using isocratic elution with a mobile phase of acetonitrile and 0.1 percent ortho phosphoric acid (70:30). A flow rate of 1 ml/min and a detector wavelength of 260 nm utilizing the PDA detector were given in the instrumental settings. Using the impurity-spiked solution, the chromatographic approach was streamlined.
Results: Validation of the proposed method was carried out according to an international conference on harmonization (ICH) guidelines. LOD and LOQ for the two active ingredients and their impurities were established with respect to test concentration. The calibration charts plotted were linear with a regression coefficient of R2 > 0.999, means the linearity was within the limit. Recovery, specificity, linearity, accuracy, robustness, ruggedness were determined as a part of method validation and the results were found to be within the acceptable range.
Conclusion: The proposed method to be fast, simple, feasible and affordable in RS condition. During stability tests, it can be used for routine analysis of production samples and to verify the quality of drug samples during stability studies.
2. Life-saving H1N1 Drug unavailable to most, CBS Evening News, Atlanta,GA,USA:CBS interactive, 2009.
3. Emergency use authorization granted for Biocryst’s Peramivir.2009
4. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous Peramivir for treatment of seasonal influenza virus infection. Antimicrob Age chemother 2010; 54:4568-74.
5. Shobugawa Y, Saito R, Sato I, Kawashima T, Dapat C, Dapat IC, et al Clinical effectiveness of neuraminidase inhibitors –oseltamivir, zanamivir, Laninamivir, and peramivir-for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the influenza season in japan. J infect chemother 2010-2011; 18:858-864.
6. Tanaka A, Seki M, Kosai K, Kawano S. Peramivir (in Japanese). Jpn j Clin Exp Med 2010; 87:1702-06.
7. McLaughlin MM, Skoglund EW, Ison MG. Peramivir: an intravenous neuraminidase inhibitor, expert Opin pharmacother, 2015; 16: 1889-900.
8. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother 2010;54: 4568-74.
9. Kohno S, Yen MY, Cheong HJ,et al. Phase III randomized, double-blind study comparing single-dose intravenous Peramivir with oral oseltamivir in patients with seasonal influenza virus infection 2011;55:5267-76.
10. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high risk patients 2011;55:2803-12.
13. Du YX, Chen XP, Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCov infection. Clinical Pharmacology and Therapeutics 2020; 108: 242-47.
14. Shiraki K, Daikoku T, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacology and Therapeutics 2020; 209: 107512.
15. Murugan S, Upendra Janardhan CH, Niranjan Babu M. RP-HPLC method for simultaneous estimation of albendazole and niclosamide in oral suspension for veterinary use. Research journal of pharmacy and technology 2016; 9: 27-32.
16. Mukta D. Naykode, Durgacharan A. Bhagwat, Swapnil D. Jadhav, Harinath N, et al. Analytical and bio analytical method for quantification of pure azilsartan, not its salt by RP-HPLC. Research journal of pharmacy and technology 2017; 10:708-14.
17. Mayanka Singh, Manoj Charde, Rajesh Shukla, Rita M. Charde. Determination of calcipotriene in calcipotriene cream 0.05% w/w by RP-HPLC method development and validation. Research journal of pharmacy and technology 2011; 4: 1219-23.
18. Murugan S, Chandra Sekhar R. Method development and validation of Fingolimod in bulk and tablet dosage form by RP-HPLC. Research journal of pharmacy and technology 2017; 10:2573-76.
19. Vani P, Vijaya Kumar B, Krishna Mohan G. Analytical Method development and validation for the determination of Allopurinol and Alphalipoic acid using reverse phase HPLC method in bulk and tablet dosage form. Research journal of pharmacy and technology 2015; 8: 207-11.
20. Palani Shanmugasundaram, Kamarapu S.K. RP-HPLC method for the simultaneous estimation and validation of amlodipine besylate and atenolol in bulk and tablet dosage form in biorelevant dissolution medium (Fassif). Research journal of pharmacy and technology 2017; 10: 3379-85.
21. Appala Raju N, Shabana Begum. Simultaneous RP-HPLC method for the estimation of the emtricitabine, tenfovir disoproxil fumerate and efavirenz in tablet dosage forms. Research journal of pharmacy and technology 2009; 522-25.
22. Ashutosh kumar S, Manidipa Debnath, Dr. Seshagiri Rao J.V.L.N, Dr. Gowri Sankar D. Development and validation of a sensitive RP-HPLC method for simultaneous estimation of rosuvastatin and fenofibrate in tablet dosage form by using PDA detector in Gradient mode. Research journal of pharmacy and technology 2016; 9: 549-54.
23. Sudha T, Shanmugasundaram P. Development and validation of RP-HPLC and HPTLC chromatographic methods of analysis for the quantitative estimation of raltegravir potassium in pharmaceutical dosage form. Research journal of pharmacy and technology 2011; 4: 1746-50.
24. Gadhvi M.P, Bhandari A, Suhagia B.N, Desai U.H. Development and validation of RP-HPLC method for simultaneous estimation of atazanavir and ritonavir in their combined tablet dosage form. Research journal of pharmacy and technology. 2013; 6:200-203.
This work is licensed under a Creative Commons Attribution 4.0 International License.